Molecular Targeted Therapy Market Report 2026

Molecular Targeted Therapy Market Overview

• Molecular Targeted Therapy market size has reached to $71.64 billion in 2025 • Expected to grow to $107.64 billion in 2030 at a compound annual growth rate (CAGR) of 8.4% • Growth Driver: The Rise Of Personalized Medicine Is Fueling The Growth Of The Market Due To Its Role In Enhancing Treatment Precision And Targeted Therapy Effectiveness • Market Trend: Breakthrough Advances In Small Molecule Inhibitors Significantly Improve Outcomes In Chemorefractory Cancers • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Molecular Targeted Therapy Market?

Molecular targeted therapy is an advanced cancer treatment that focuses on blocking the growth and spread of cancer cells by interfering with specific molecules involved in tumor development. Tailored to the genetic and molecular characteristics of a patient’s tumor, this approach aims to enhance treatment effectiveness while minimizing harm to healthy cells. By targeting cancer-specific pathways, it offers a more precise and less toxic alternative to conventional therapies. The main types of molecular targeted therapy are monoclonal antibodies, small molecule inhibitors, gene therapy, and cell therapy. Monoclonal antibodies are engineered proteins that precisely target and destroy cancer cells while sparing healthy tissue in molecular targeted therapy. It is administered through various modes of administration, such as oral, injectable, topical, and intravenous, for several applications, including lung cancer, breast cancer, colorectal cancer, leukemia, and others, and is used by several end-users, such as hospitals, clinics, research laboratories, and diagnostic centers.

What Is The Molecular Targeted Therapy Market Growth Forecast?

The molecular targeted therapy market size is expected to see strong growth in the next few years. It will grow to $107.64 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to personalized cancer treatment growth, next-generation sequencing adoption, AI-driven drug discovery, global oncology burden, targeted therapy reimbursement. Major trends in the forecast period include expansion of precision oncology, increased adoption of biomarker-based therapies, growth of targeted cancer drug pipelines, integration of companion diagnostics, rising use of combination targeted therapies.

What Is The Driver Of The Molecular Targeted Therapy Market?

The rise of personalized medicine is expected to propel the growth of the molecular targeted therapy market going forward. Personalized medicine is a healthcare approach that customizes treatment and prevention based on an individual’s genetic profile, lifestyle, and environmental factors. Personalized medicine is rising due to increasing genetic data availability, enabling treatments tailored to individual genomes for better efficacy and fewer side effects. Personalized medicine supports molecular targeted therapy by analyzing a patient’s tumor for specific genetic mutations or biomarkers, allowing for the selection of therapies that directly target those abnormalities. This approach improves treatment precision and reduces harm to healthy tissues. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the rise of personalized medicine is driving the growth of the molecular targeted therapy industry.

Key Players In The Global Molecular Targeted Therapy Market

Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

Global Molecular Targeted Therapy Market Trends and Insights

Major companies operating in the molecular targeted therapy market are focusing on developing advanced products such as small molecule inhibitors to improve patient outcomes in various cancers and chronic diseases. Small molecule inhibitors are tiny compounds that can easily penetrate cells and inhibit specific proteins that drive disease. For instance, in January 2025, Amgen Inc., a US-based pharmaceutical company, introduced Lumakras (sotorasib) in combination with Vectibix (panitumumab), which received approval from the US Food and Drug Administration (FDA), a US-based government organization. It is designed for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as determined by an FDA-approved test. This approval is based on the Phase 3 CodeBreaK 300 trial, which showed that the combination more than doubled progression-free survival compared to the investigated standard of care, making it the first targeted therapy to show such benefit in this chemorefractory patient population.

What Are Latest Mergers And Acquisitions In The Molecular Targeted Therapy Market?

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. With this acquisition, Pfizer aims to enhance its oncology portfolio and accelerate the development of innovative cancer therapies by integrating Seagen’s expertise in antibody-drug conjugate (ADC) technology. Seagen Inc., a US-based company that develops monoclonal antibody-based therapies for the treatment of cancer.

What Defines the Molecular Targeted Therapy Market?

The molecular targeted therapy market consists of sales of targeted cancer drugs, kinase inhibitors, hormone therapies, and companion diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Molecular Targeted Therapy Market Report 2026?

The molecular targeted therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the molecular targeted therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.